Article may be outdated

This article is 3 days old. Some details may have changed since publication.

The Hindu·2 min read·medium

USFDA concludes inspection at Zydus’ LiqMeds in U.K. with four observations

P
PTI
USFDA concludes inspection at Zydus’ LiqMeds in U.K. with four observations
✦AI Summary

The US Food and Drug Administration has concluded an inspection of Zydus Lifesciences' LiqMeds facility in the U.K., issuing four observations. The company has committed to working with regulators to address these findings promptly.

Why it matters

Regulatory observations from the USFDA can impact a pharmaceutical company's operational compliance and market access, often influencing investor confidence.

✦Dive DeeperCreate a free account to unlock

New Delhi Zydus Lifesciences on Saturday (November 14, 2026) said the U.S. health regulator has concluded its inspection at LiqMeds, U.K., with four observations. The inspection was conducted from November 9-13, the company said in a regulatory filing to stock exchanges. "The company will closely work with the U.S.

Continue reading on Headlinne

Create a free account to read the full article.

Read full article →
businesshealth
✦

Get smarter about the news

Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.

Create free account

Already have an account? Sign in